Zobrazeno 1 - 10
of 51
pro vyhledávání: '"Karim Malek"'
Publikováno v:
BioNanoScience; Mar2024, Vol. 14 Issue 1, p153-163, 11p
Autor:
Carole Helissey, Sophie CAVALLERO, Nathalie GUITARD, Hélène THERY, Charles PARNOT, Antoine SCHERNBERG, Imen AISSA, Florent RAFFIN, Catherine LE COZ, Stanislas MONDOT, Christos Christopoulos, Karim MALEK, Emmanuelle MALAURIE, Pierre Blanchard, Cyrus CHARGARI, Sabine FRANCOIS
BACKGROUND Despite advances in radiation techniques, radiation cystitis (RC) remains a significant cause of morbidity from pelvic radiotherapy, which may affect patients' quality of life (QoL). The pathophysiology of RC is not well understood, which
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::ae520aeb7b185ed3dfa06395293b4c70
https://doi.org/10.2196/preprints.48225
https://doi.org/10.2196/preprints.48225
Autor:
David Aggen, Meredith McKean, Nehal Lakhani, Babar Bashir, Jean Hoffman-Censits, Omar Alhalabi, Elizabeth Guancial, Isaac Bowman, Alan Tan, Trupti Lingaraj, Marissa Timothy, Nerymar Ortiz-Otero, Wilmin Bartolini, Katherine Kacena, Karim Malek, Sergio Santillana, Jason Luke
Publikováno v:
Regular and Young Investigator Award Abstracts.
Autor:
Trupti Lingaraj, Marissa Timothy, Nerymar Ortiz-Otero, Wilmin Bartolini, Katherine Kacena, Karim Malek, Sergio Santillana
Publikováno v:
Regular and Young Investigator Award Abstracts.
Autor:
Carole Helissey, Sophie Cavallero, Nathalie Guitard, Hélène Thery, Charles Parnot, Antoine Schernberg, Stanislas Mondot, Christos Christopoulos, Karim Malek, Emmanuelle Malaurie, Cyrus Chargari, Sabine Francois
Publikováno v:
Journal of Clinical Oncology. 41:344-344
344 Background: Despite improvements in radiation techniques, pelvic radiotherapy is responsible for acute and delayed bladder adverse events, defined as radiation cystitis (CysR). About 50% of irradiated patients present acute symptoms and experienc
Autor:
Ursula A. Matulonis, Gina Mantia-Smaldone, Cesar M. Castro, Lainie P. Martin, Antonio Gonzalez Martin, Ignace Vergote, Michael J. Birrer, Kathleen N. Moore, Richard T. Penson, Karim Malek, Raquel Bratos, Lucy Gilbert, David M. O'Malley
Publikováno v:
Gynecologic Oncology. 157:379-385
Purpose To evaluate the safety and clinical activity of mirvetuximab soravtansine, an antibody-drug conjugate comprising a humanized anti-folate receptor alpha (FRα) monoclonal antibody, cleavable linker, and the maytansinoid DM4, a potent tubulin-t
Publikováno v:
BioNanoScience; 20230101, Issue: Preprints p1-11, 11p
Autor:
Karim Malek, Kathleen N. Moore, Michael J. Birrer, Lainie P. Martin, Ignace Vergote, Antonio González-Martín, David M. O'Malley
Publikováno v:
Gynecologic Oncology. 151:46-52
PURPOSE: To evaluate the safety profile and preliminary antitumor activity of mirvetuximab soravtansine when administered in combination with carboplatin to relapsed ovarian cancer patients. METHODS: Patients with recurrent, platinum-sensitive epithe
Autor:
Nicoletta Colombo, Ignace Vergote, Karim Malek, Kathleen N. Moore, Michael J. Birrer, Amit M. Oza, Susana Banerjee, Ana Oaknin, Patricia Pautier
Publikováno v:
Future Oncology. 14:1669-1678
Mirvetuximab soravtansine, an antibody-drug conjugate that binds with high affinity to folate receptor-α to provide tumor-directed delivery of the potent microtubule-disrupting agent DM4, has emerged as a promising investigational agent for the trea
Autor:
Xin Gao, Neil Lineberry, Kristin Horn, Gerald Steven Falchook, Michael Shaw, James Strauss, John Gibbs, Karim Malek, Richard C. Gregory, Kate Stumpo, Cong Li, Anthony J. Olszanski, Patricia LoRusso, Pei Jye Voon, Jason J. Luke
Publikováno v:
Journal of Clinical Oncology. 39:TPS2670-TPS2670
TPS2670 Background: Immuno-oncology therapies, including immune checkpoint inhibitors (CPIs), are revolutionizing cancer treatment. However, primary and secondary resistance to CPIs remains a significant challenge. CPI resistance has been associated